Lumosa Therapeutics and CHI Memorial announce new study for acute stroke
Patients receiving Lumosa Therapeutics' stroke drug were not at an increased risk for a serious brain hemorrhage, meeting the trial's main goal.
TAIPEI, Dec. 21, 2020 /PRNewswire/ -- Lumosa Therapeutics is pleased to announce the market approval of LT1001 (Naldebain®), an extended-release analgesic injection, from Singapore's Health Science Agency (HSA). HSA is regarded as one of the regulatory reference countries in the world. The approval from Singapore has significance in accelerating the introduction of LT1001 in Southeast Asia.